SRG OncoRat , developed using Hera Biolabs’ technology, is a SCID rat on the Sprague-Dawley background that harbors a double knockout for the Rag2 and Il2rgamma genes. Similar to NSG mice, OncoRat demonstrates enhanced immunodeficiency, lacking B-cells, T-cells, and NK-cells. Combining these genetic changes in this immunodeficient rat allows the use of fewer animals through enhanced engraftment rates and improved tumor growth profiles for both cell-line tumor models and patient-derived xenografts (PDXs) (Figure 1). Given the many advantages of using SCID rats, OncoRat is an ideal model for combining efficacy, pharmacokinetic (PK), biomarker, and toxicology-related endpoints.
OncoRat engrafts human tumors at a higher rate with more uniform tumor kinetics, providing translational scientists with the tools they need for rapid decision-making.
Hera BioLabs’ OncoRat allows a smooth transition from efficacy to safety evaluation. It pairs well with nonclinical rat safety models, reducing the need for cross-species assessment.
Tumors grow 10x larger in OncoRat, facilitating more options for downstream analyses. Also, the ability to perform serial blood draws and tumor biopsies generate more data with fewer animals.
Boost your preclinical research with SRG OncoRat, a SCID rat delivered directly from our colony at Charles River Labs with VAF/Elite health status.
SCID rats also have another clear benefit for translational physiology and toxicology studies: size. Specifically, their larger mass allows more options for dose administration (e.g., continuous infusions, devices). For data collection, OncoRat can sustain serial blood sampling and serial tumor biopsies from the larger tumors grown. Ultimately, this enables richer PK and biomarker metrics over time. There’s no need to remove animals from studies or run studies in both mice and rats, as is the case with many oncology xenograft models. Researchers can use the same rats to complete a single time-course experiment.